Recent Updates
Recently added Catalysts

BX002-A

Phase 1

Healthy Volunteers | Monoclonal antibody | Other |BiomX Inc.|Last Updated: Jan 25, 2022

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedPLACEBO_CONTROLLED
Total Trials1
Total Enrollment18
FDA Designations
No designations recorded
Clinical trial landscape

BX002-A · 1 trial · 1 indication

Phase 1 1
NCT04737876A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy AdultsHealthy Volunteers
COMPLETED18 Analytics
PHASE1COMPLETED
A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults
Healthy Volunteers
NCT0473787618
Unlock trial analytics
Study Endpoints
Primary Endpoints
Safety and Tolerability: adverse events
Through study completion Day 31 (+ 2 days)

Evaluated by reviewing adverse events

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeOTHER
Treatment Arms
ArmTypeDescription
BX002-AEXPERIMENTALBX002-A: 1 mL liquid for multiple dose oral administration
PlaceboPLACEBO_COMPARATORPlacebo: 1 mL liquid for multiple dose oral administration
Interventions
NameTypeDescription
BX002-ABIOLOGICALbacteriophage cocktail
PlaceboOTHERPlacebo
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy adults 18-65 years old 2. Able to understand study procedures and sign informed consent Exclusion Criteria: 1. Evidence or history of clinically significant underlying conditions 2. Women who are pregnant or nursing, or plan to become pregnant during study, or women...

Countries:United States
Unlock Eligibility Criteria